



# sCD95 (APO1/Fas) ELISA KIT

## INTENDED USE

The Human soluble CD95 (sCD95) ELISA is to be used for the in-vitro quantitative determination of soluble CD95 (APO-1, Fas) in human serum, plasma, buffered solutions or cell culture medium. The assay will recognize both natural and recombinant human sCD95. **This kit has been configured for research use only and is not to be used in diagnostic procedures.**

## PRINCIPLE OF THE METHOD

The sCD95 Kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A monoclonal antibody specific for sCD95 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known sCD95 concentrations, and unknowns are pipetted into these wells.

During the first incubation, the sCD95 antigen and a biotinylated monoclonal antibody specific for sCD95 are simultaneously incubated. After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove all the unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of sCD95 present in the samples.

## REAGENTS PROVIDED AND RECONSTITUTION

REAGENTS (Store at 2-8°C)	COLOUR CODE	1x96 wells Cat # 850.740.096	2x96 wells Cat # 850.740.192	RECONSTITUTION
96-wells microtiter plates		1	2	Ready-to-use
Plastic cover		2	4	
Standard : 3000 pg/ml	Yellow	2 vials	4 vials	Reconstitute with the volume of standard diluent indicated on the vial. (See Reagents Preparation on page 2)
Control	Silver	2 vials	4 vials	Reconstitute with the volume of standard diluent indicated on the vial. (See Reagents Preparation on page 2)
Standard Diluent Buffer	Black	1 vial	1 vial	(25 ml) 10X concentrate. Dilute in distilled Water.
Biotinylated anti-sCD95	Red	1 vial	2 vials	(0.4 ml) Dilute in biotinylated antibody diluent
Biotinylated Antibody Diluent	Red	1 vial (7.5 ml)	1 vial (13 ml)	Ready-to-use
Streptavidin-HRP		2 vials	4 vials	(5 µl) 0.5ml of HRP-Diluent before further dilutions
HRP Diluent	Red	1 vial	1 vial	(23 ml) Ready-to-use
Washing Buffer	White	1 vial	2 vials	(10 ml) 200X concentrate. Dilute in distilled Water
Chromogen TMB :		1 vial (11 ml)	1 vial (24 ml)	Ready-to-use
H2SO4 : Stop Reagent	Black	1 vial	2 vials	(11 ml) Ready-to-use

## MATERIAL REQUIRED BUT NOT PROVIDED

- \* Distilled water.
- \* Pipettes : 10 µl, 50 µl, 100 µl, 200 µl and 1000 µl.
- \* Vortex mixer and magnetic stirrer.

## SAFETY

- \* For research use only.
- \* The human blood components included in this kit have been tested and found non reactive for HBsAg and anti-HIV. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore, handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g. CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984.
  - \* Avoid any skin contact with H<sub>2</sub>SO<sub>4</sub> and TMB. In case of contact, wash thoroughly with water.
  - \* Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
  - \* Do not pipette by mouth.

**PROCEDURAL NOTES/LAB. QUALITY CONTROL**

1. When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels. All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use.
2. Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration.
3. Cover or cap all reagents when not in use.
4. Do not mix or interchange reagents between different lots.
5. Do not use reagents beyond the expiration date of the kit.
6. Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross-contamination ; for the dispensing of H<sub>2</sub>SO<sub>4</sub> and substrate solution, avoid pipettes with metal parts.
7. Use a clean plastic container to prepare the washing solution.
8. Thoroughly mix the reagents and samples before use by agitation or swirling.
9. All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
10. The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly.
11. If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbances within 1 hour after completion of the assay.
12. When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells.
13. Respect incubation times described in the assay procedure.
14. Dispense the TMB solution within 15 min. following the washing of the microtiter plate.

**SPECIMEN COLLECTION, PROCESSING AND STORAGE**

**Cell culture supernatants**- Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

**Serum**-Avoid any unintentional stimulation of the cells by the procedure. Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. For that, after clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

**Plasma**-EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

**Storage**-If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

When possible, avoid use of badly hemolyzed or lipemic sera. If large amounts of particles are present, this should be removed prior to assay by centrifugation or filtration.

**Recommendation** : Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before assaying

**PREPARATION OF REAGENTS****Standard buffer diluent 10X concentrate**

Dilute 10 times with distilled water before use.

**Standards**

Standard have to be reconstituted with the volume of standard buffer diluent indicated on the vial. This reconstitution produces a stock solution of 3000 pg/ml sCD95. Allow standard to stand for 5 minutes with gentle swirling prior to making dilutions. **Make sure that all aggregates are back into solution. Pipette up and down several times in order to dissolve all clumps.** Serial dilutions of standard must be made before each assays and cannot be stored.

**Controls**

Control have to be reconstituted with the volume of standard buffer diluent indicated on the vial. Reconstitution of the freeze-dried material with the indicated volume, will give a solution for which the sCD95 concentration is stated on the vial. Allow control to stand for 5 minutes with gentle swirling prior to distribute in control wells. Do not store after use.

**Dilution of biotinylated anti-sCD95**

Preparation immediately before use is recommended. Dilute the biotinylated anti-sCD95 with the biotinylated antibody diluent in a clean glass vial according to the number of wells to be used. See the next table for volumes to pipette. Extemporaneous preparations are recommended.

Number of Wells used	Biotinylated Antibody (µl)	Biotinylated Antibody Diluent (µl)
16	40	1060
24	60	1590
32	80	2120
48	120	3180
96	240	6360

Dilution of Streptavidin-HRP

**Add 0.5 ml of HRP diluent to a 5 µl vial of Streptavidin-HRP . DO NOT KEEP THIS DILUTION FOR FURTHER EXPERIMENTS.** Dilute immediately before use. Following the number of wells to be used, further dilutions of Streptavidin-HRP should be made with HRP diluent in a clean glass vial : see hereafter the table for volumes to pipette.

Number of Wells	Streptavidin-HRP(µl)	Strep-HRP Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

Washing Buffer 200X concentrate

Dilute 200 times in distilled water.

**ASSAY METHOD**


- a) Before use, mix all reagents thoroughly without making foam.
- b) Determine the number of microwell strips required to test the desired number of samples, plus appropriate number of wells needed for running blanks standards and controls. Each sample, standard, blank and control samples should be assayed in duplicate. Remove sufficient microwell strips from the pouch.
- c) Add 100 µl of appropriate standard diluent (see preparation of reagents) to standard wells B1, B2, C1, C2, D1, D2, E1, E2, F1, F2. Reconstitute standard vial with the appropriate volume as described in the chapter reagents preparation. Pipet 200 µl of standard into wells A1 and A2 (see Plate Scheme below). Transfer 100 µl from A1 and A2 to B1 and B2 wells. Mix the contents by repeated aspirations and ejections. Take care not to scratch the inner surface of microwells. Repeat this procedure from the wells B1, B2 to wells C1, C2 and from wells C1, C2 to D1, D2 and so on creating two parallel rows of sCD95 standard dilutions ranging from 3000 to 93.75 pg/ml. Discard 100 µl from the content of the last microwells used (F1, F2).  
Alternatively these dilutions can be done in separate tube and diluted standard pipetted directly into wells.
- d) Add 100 µl of appropriate standard diluent to the blank wells ( G1-G2 ).
- e) Add 100 µl of sample to sample wells and 100µl of reconstituted control vial to control wells (H1 , H2).
- f) Preparation of biotinylated anti-sCD95 : (see preparation of reagents).
- g) Add 50 µl of diluted biotinylated anti-sCD95 to all wells.
- h) Cover with a plate cover and incubate for 1 hour at room temperature ( 18°C - 25°C ).
- i) Remove the cover and wash the plate as follows:
  - 1) aspirate the liquid from each well ;
  - 2) dispense 0.3 ml of washing solution into each well ;
  - 3) aspirate again the content of each well ;
  - 4) Repeat steps 2) and 3) two times.
- j) Prepare streptavidin-HRP solution just before use : (see preparation of reagents).
- k) Distribute 100µl of streptavidin-HRP solution to all wells, including blank wells.
- l) Cover and incubate 30 min at room temperature.
- m) Remove the cover and empty wells. Wash microwell strips according to step i). Proceed immediately to the next step.
- n) Pipette 100 µl of ready-to-use TMB substrate solution into all wells, including the blank wells and incubate in the dark for 20-30 minutes at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil.
- o) Incubation time of the substrate solution is usually determined by the ELISA reader performances: many ELISA readers record absorbance only up to 2.0 O.D. The O.D. values of the plate should be monitored and the substrate reaction stopped before positive wells are no longer properly readable (maximum 20 minutes).
- p) The enzyme-substrate reaction is stopped by quickly pipetting 100 µl of H<sub>2</sub>SO<sub>4</sub> : stop reagent into each well, including the blank wells, to completely and uniformly inactivate the enzyme. Results must be read immediately after the addition of H<sub>2</sub>SO<sub>4</sub> : stop reagent, or within one hour, if the microwell strips are stored at 2-8°C in the dark.
- q) Read absorbance of each well on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm (610 nm to 650 nm is acceptable) as the reference wavelength.

**SUGGESTED PLATE SCHEME**

	Standard Concentrations pg/mL		Sample wells									
	1	2	3	4	5	6	7	8	9	10	11	12
A	3000	3000										
B	1500	1500										
C	750	750										
D	375	375										
E	187.5	187.5										
F	93.75	93.75										
G	Blank	Blank										
H	Ctrl	Ctrl										

**DATA ANALYSIS**

Generate a linear standard curve by plotting the average absorbance on the vertical axis versus the corresponding sCD95 standard concentration on the horizontal axis. The amount of sCD95 in each sample is determined by extrapolating OD values to sCD95 concentrations using the standard curve.



**Typical sCD95 standard curve ranging from 93.75 to 3000 pg/mL**

**LIMITATIONS OF THE PROCEDURE**

Do not extrapolate the standard curve beyond the 3000 pg/ml standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples (> 3000 pg/ml) have to be diluted with standard diluent or with your own sample buffer. During analysis, multiply results by the appropriate dilution factor.

The influence of various drugs, aberrant sera (hemolyzed, hyperlipidemic, jaundiced...) has not been investigated.. The rate of degradation of native sCD95 in various matrices has not been investigated.

**PERFORMANCES AND CHARACTERISTICS**

**Sensitivity**


The minimum detectable dose of is less than 47 pg/ml. This has been determined by adding 3 standard deviations to the mean optical density obtained when the zero standard was assayed 40 times.

**Precision**

**Intra-Assay**

**Inter-Assay**

Sample	n	Mean (pg/mL)	SD	CV%	Sample	n	Mean (pg/mL)	SD	CV%
A	14	1719	106	6.1	A	8	1752	145	8.2
B	16	703	39	5.5	B	8	856	68	7.9

**ASSAY PROCEDURE SUMMARY** Total procedure length : 1h45mn

**REFERENCES**

- Cheng, J. et al. (1994) : Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* 263 : 1759-1762.
- Cascino, I. et al. (1995) : Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. *J. Immunol* 154 : 2706-2713.
- Knipping, E. et al. (1995) : Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. *Athritis Rheum* 38 : 1735-1737.
- Midis, GP. et al. (1996) : Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. *Cancer Res* 56 : 3870-3874.
- Fadeel, B. et al. (1996) : Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals. *Blood* 88 : 4727-4730.
- Jodo, S. et al. (1997) : Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. *Clin. Exp. Immunol.* 107 : 89-95.
- Nozawa et al. (1997) : Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. *Arthritis and rheumatism.* 40 : 1126-1129.
- Jian, JD. et al. (1997) : Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. *J. Clin. Immunol.* 17 : 185-192.
- Liem, LM. et al. (1998) : Soluble Fas levels in sera of bone marrow transplantation recipients are increased during graft-versus-host disease but not during infections. *Blood* 91 : 1464-1468.
- Toyozaki, T. et al. (1998) : Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. *Am. J. Cardio.* 81 : 798-800.
- Iio, S. et al. (1998) : Serum levels of soluble Fas in chronic hepatitis C patients. *J. Hepatol.* 29 : 517-523.
- Yufu, Y. et al. (1998) : Soluble Fas in the serum of patients with non-Hodgkin's lymphomas : higher concentrations in angioimmunoblastic T-cell lymphoma. *Am. J. Hematol.* 58 : 334-336.
- Van Lopik, T. (1999). : Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. *J. Rheumatol.* 26 : 60-67.
- Srivastava, MD. et al. (1999) : Soluble Fas and soluble Fas ligand proteins in human milk : possible significance in the development of immunological tolerance. *Scand. J. Immunol.* 49 : 51-54.
- Shou, I. et al. (1999) : Serum levels of soluble Fas and disease activity in patients with IgA nephropathy. *Nephron* 81 : 387-392.